Literature DB >> 12089561

Targeted transgene insertion into human chromosomes by adeno-associated virus vectors.

Roli Hirata1, Joel Chamberlain, Rong Dong, David W Russell.   

Abstract

Efficient methods are needed for the precise genetic manipulation of diploid human cells, in which cellular senescence and low conventional gene targeting rates limit experimental and therapeutic options. We have shown previously that linear, single-stranded DNA vectors based on adeno-associated virus (AAV) could accurately introduce small (<20 bp) genetic modifications into homologous human chromosomal sequences. Here we have used AAV vectors to introduce large (>1 kb) functional transgene cassettes into the hypoxanthine phosphoribosyl transferase (HPRT) and Type I collagen (COL1A1) loci in normal human fibroblasts. The transgene cassettes are inserted at high frequencies (1% of the total cell population under optimal conditions) and without secondary mutations. Selection for the inserted transgene cassette can be used to enrich for targeting events, such that >70% of surviving cells have undergone gene targeting with an appropriately designed vector. This approach should prove useful both for functional genomic analysis in diploid human cells and for therapeutic gene targeting.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12089561     DOI: 10.1038/nbt0702-735

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


  75 in total

1.  Efficient gene targeting mediated by adeno-associated virus and DNA double-strand breaks.

Authors:  Matthew H Porteus; Toni Cathomen; Matthew D Weitzman; David Baltimore
Journal:  Mol Cell Biol       Date:  2003-05       Impact factor: 4.272

2.  Facile methods for generating human somatic cell gene knockouts using recombinant adeno-associated viruses.

Authors:  Manu Kohli; Carlo Rago; Christoph Lengauer; Kenneth W Kinzler; Bert Vogelstein
Journal:  Nucleic Acids Res       Date:  2004-01-02       Impact factor: 16.971

3.  Discriminatory suppression of homologous recombination by p53.

Authors:  Sheng Yun; Chadwick Lie-A-Cheong; Andrew C G Porter
Journal:  Nucleic Acids Res       Date:  2004-12-15       Impact factor: 16.971

4.  The colorectal microRNAome.

Authors:  Jordan M Cummins; Yiping He; Rebecca J Leary; Ray Pagliarini; Luis A Diaz; Tobias Sjoblom; Omer Barad; Zvi Bentwich; Anna E Szafranska; Emmanuel Labourier; Christopher K Raymond; Brian S Roberts; Hartmut Juhl; Kenneth W Kinzler; Bert Vogelstein; Victor E Velculescu
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-27       Impact factor: 11.205

5.  Synthesis of programmable integrases.

Authors:  Russell M Gordley; Charles A Gersbach; Carlos F Barbas
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-12       Impact factor: 11.205

Review 6.  Knockout punches with a fistful of zinc fingers.

Authors:  John H Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-09       Impact factor: 11.205

7.  Targeted genetic modification of cell lines for recombinant protein production.

Authors:  Niall Barron; Olga Piskareva; Mohan Muniyappa
Journal:  Cytotechnology       Date:  2007-02-28       Impact factor: 2.058

Review 8.  Recombinant adeno-associated virus transduction and integration.

Authors:  Brian R Schultz; Jeffrey S Chamberlain
Journal:  Mol Ther       Date:  2008-05-20       Impact factor: 11.454

9.  An experimental system for the evaluation of retroviral vector design to diminish the risk for proto-oncogene activation.

Authors:  Byoung Y Ryu; Marguerite V Evans-Galea; John T Gray; David M Bodine; Derek A Persons; Arthur W Nienhuis
Journal:  Blood       Date:  2007-11-08       Impact factor: 22.113

10.  Werner syndrome protein limits MYC-induced cellular senescence.

Authors:  Carla Grandori; Kou-Juey Wu; Paula Fernandez; Celine Ngouenet; Jonathan Grim; Bruce E Clurman; Michael J Moser; Junko Oshima; David W Russell; Karen Swisshelm; Scott Frank; Bruno Amati; Riccardo Dalla-Favera; Raymond J Monnat
Journal:  Genes Dev       Date:  2003-07-01       Impact factor: 11.361

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.